John Brabant, PA
Medical · Detroit, MINPI 1629448527
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Novo Nordisk at 53.5% of the total. Reporting peaked in 2022 at $16,984 and has fallen 95.6% since, to $749 in 2025. Among medical clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $154.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$14K
- Bayer$10K
- Lilly USA, LLC$286
- AbbVie$153
- Otsuka America Pharmaceutical, Inc.$141
- Exact Sciences$123
- plus $949 from 20 others
What the payments were for
- Consulting fees$7,98331%
- Speaking & faculty fees$10,42240%
- Travel & lodging$3,79315%
- Food & beverage$3,63514%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $13,827 |
| Bayer | 33 | $10,365 |
| Lilly USA, LLC | 16 | $286 |
| AbbVie | 8 | $153 |
| Otsuka America Pharmaceutical, Inc. | 6 | $141 |
| Exact Sciences | 6 | $123 |
| AstraZeneca(2 entities) | 7 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $89 |
| Merck | 4 | $88 |
| GSK | 5 | $76 |
| Pfizer | 4 | $76 |
| Amgen | 4 | $72 |
| Novartis | 3 | $65 |
| Astellas Pharma US Inc | 4 | $62 |
| Corium, LLC | 3 | $62 |
| Abbott | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
| Amarin Pharma, Inc. | 1 | $23 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,845 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $59,711 |
| MounjaroTirzepatide | 47 | $58,792 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $40,372 |
| EliquisApixaban | 25 | $32,045 |
| JardianceEmpagliflozin | 25 | $31,526 |
| RybelsusSemaglutide | 17 | $22,692 |
| FarxigaDapagliflozin Propanediol | 15 | $20,561 |
| XareltoRivaroxaban | 14 | $15,501 |
| EntrestoSacubitril/Valsartan | 13 | $13,033 |
| MyrbetriqMirabegron | 11 | $10,861 |
| JanuviaSitagliptin Phosphate | 11 | $9,989 |
| Atorvastatin Calcium | 282 | $4,834 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $3,306 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,091 |
| Omeprazole | 128 | $2,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $13,827 | $82,40355 claims |
| Lilly USA, LLCMounjaro | $286 | $58,79247 claims |
| GSKTrelegy Ellipta | $76 | $40,37242 claims |
| PfizerEliquis | $76 | $32,04525 claims |
| AstraZenecaFarxiga | $116 | $20,56115 claims |
| NovartisEntresto | $65 | $13,03313 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $10,86111 claims |
| MerckJanuvia | $88 | $9,98911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.
Other medical in Detroit
- Kimberly BelzerDetroit$16K
- Linda RyznarDetroit$16K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.